Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

Helena Record; Elle Clelland; Harriet T Rothschild; Mandeep Kaur; A Jo Chien; Michelle Melisko; Hope S Rugo; Firdows Mujir; Laura Huppert; Rita A Mukhtar

doi:10.1038/s41523-023-00594-3

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

NPJ Breast Cancer. 2023 Oct 26;9(1):88. doi: 10.1038/s41523-023-00594-3.

Authors

Affiliations

¹ Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
² School of Medicine, University of California San Francisco, San Francisco, CA, USA.
³ Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
⁴ Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA, USA.
⁵ Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA, USA. Rita.mukhtar@ucsf.edu.

Abstract

While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer, recent trials showed a benefit of aromatase inhibitors (AI) and ovarian function suppression (OFS) for some patients. The approach to endocrine therapy has not been well studied in pre-menopausal patients with invasive lobular carcinoma (ILC). We identified 202 pre-menopausal patients with HR positive stage I-III ILC in an institutional database. We investigated factors associated with endocrine therapy type and determined changes in systemic therapy from 1990-2021. We evaluated associations between endocrine therapy type and disease-free survival (DFS) with a multivariate Cox proportional hazards model. Of 202 patients, most (69.3%) were prescribed a SERM (99.3% tamoxifen). Those who received an AI had significantly higher stage disease. Over time, use of OFS and AI increased significantly in stage II or III cases (from 0% in 1990 to 56% after 2015 for stage II; from 0% to 80% after 2015 for stage III). Concurrently, adjuvant chemotherapy use significantly decreased in stage II cases (from 67% to 19%). In an exploratory multivariable model, longer duration of AI compared to tamoxifen was associated with significantly improved DFS (HR 0.31; 95% CI 0.11-0.86; p = 0.025). While most pre-menopausal patients received adjuvant tamoxifen, the use of OFS and AIs increased significantly over time. The association between AI use and improved DFS may be consistent with prior randomized trials and warrants further investigation into predictive factors to guide treatment selection.

Grants and funding

K08 CA256047/CA/NCI NIH HHS/United States